Uwaifo Gi Fallon Em Diabetes Care 2002 25 2081-7

The Big Diabetes Lie

Diabetes Diet Plan

Get Instant Access

[1] Bergman RN, Ader M, Huecking K, et al. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(Suppl 1):S212-20.

[2] Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-69.

[3] Bruning JC, Winnay J, Bonner-Weir S, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997;88:561-72.

[4] Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005;307:1909-14.

[5] Porte Jr D, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005;54: 1264-76.

[6] Schwartz MW, Porte Jr D. Diabetes, obesity, and the brain. Science 2005;307:375-9.

[7] Rossi J, Santamaki P, Airaksinen MS, et al. Parasympathetic innervation and function of endocrine pancreas requires the glial cell line-derived factor family receptor alpha2 (GFRalpha2). Diabetes 2005;54:1324-30.

[8] Kemp DM, Thomas MK, Habener JF. Developmental aspects of the endocrine pancreas. Rev Endocr Metab Disord 2003;4:5-17.

[9] Amiel SA, Caprio S, Sherwin RS, et al. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991;72:277-82.

[10] Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-91.

[11] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495-522.

[12] Williams DL, Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 2005;135:1320-5.

[13] Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-66.

[14] Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 2005;128:149-57.

[15] Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-73.

[16] Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005;6: 181-9.

[17] Heptulla RA, Rodriguez LM, Bomgaars L, et al. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-7.

[18] Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 2004;287:E371-85.

[19] Gabbay KH. The insulinopathies. N Engl J Med 1980;302:165-7.

[20] Sperling MA. Insulin biosynthesis and C-peptide: practical applications from basic research. Am J Dis Child 1980;134:1119-21.

[21] Hussain K, Cosgrove KE. From congenital hyperinsulinism to diabetes mellitus: the role of pancreatic (-cell Katp channels. Pediatr Diabetes 2005;1:1-11.

[22] Porter JR, Barrett TG. Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of pathology of insulin resistance and beta cell failure. J Med Genet 2005:16.

[23] Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.

[24] Uwaifo GI, Fallon EM, Chin J, et al. Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care 2002;25:2081-7.

[25] Gungor N, Saad R, Janosky J, et al. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 2004;144:47-55.

[26] Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996;22:397-406.

[27] Greenbaum C, Seidel K, Pihoker C. The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care 2004;27:1202-4.

[28] Yeckel CW, Weiss R, Dziura J, et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004; 89:1096-101.

[29] Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3.

[30] Conwell LS, Trost SG, Brown WJ, et al. Indexes of insulin resistance and secretion in obese children and adolescents: a validation study. Diabetes Care 2004;27:314-9.

[31] Cutfield WS, Bergman RN, Menon RK, et al. The modified minimal model: application to measurement of insulin sensitivity in children. J Clin Endocrinol Metab 1990;70:1644-50.

[32] Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67.

[33] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

[34] Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2.

[35] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.

[36] Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85: 2402-10.

[37] Perseghin G, Caumo A, Caloni M, et al. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab 2001;86:4776-81.

[38] Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19: 527-34.

[39] Soonthornpun S, Setasuban W, Thamprasit A, et al. Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab 2003;88:1019-23.

[40] Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.

[41] Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998;63:134-41.

[42] Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990;10:167-75.

Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 2000;47:177-84. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.

Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-10.

Maassen JA, 't Hart LM, Van Essen E, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004;53(Suppl 1):S103-9.

Ohkubo K, Yamano A, Nagashima M, et al. Mitochondrial gene mutations in the tRNA(Leu(UUR)) region and diabetes: prevalence and clinical phenotypes in Japan. Clin Chem 2001;47:1641-8.

Moraes CT, Ricci E, Bonilla E, et al. The mitochondrial tRNA(Leu(UUR)) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle. Am J Hum Genet 1992;50:934-49. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab 2003;14:371-7.

Oral EA. Lipoatrophic diabetes and other related syndromes. Rev Endocr Metab Disord 2003;4:61 -77.

Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the

National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-8.

Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004;


Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.

Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.

Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8.

Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.

Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381 -9.

Landin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002;958: 112-6.

Weyer C, Tataranni PA, Bogardus C, et al. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001;24:89-94.

Lanng S, Hansen A, Thorsteinsson B, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995;311:655-9.

Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med 2003; 20:425-36.

Holl RW, Wolf A, Thon A, et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1997;25:188-93. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004;21:691 -6.

[66] Yung B, Noormohamed FH, Kemp M, et al. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002;19:221-6.

[67] Holl RW, Heinze E, Wolf A, et al. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr 1995;154: 356-61.

[68] De Schepper J, Hachimi-Idrissi S, Smitz J, et al. First-phase insulin release in adult cystic fibrosis patients: correlation with clinical and biological parameters. Horm Res 1992;38:260-3.

[69] Polychronakos C. Early onset diabetes mellitus: tip or iceberg? Pediatr Diabetes 2004;5:171-3.

[70] Austin A, Kalhan SC, Orenstein D, et al. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab 1994;79: 80-5.

[71] Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994; 43:1020-6.

[72] Lombardo F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 2003;149:53-9.

[73] Cucinotta D, De Luca F, Gigante A, et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur J Endocrinol 1994;130:253-8.

[74] Lanng S, Thorsteinsson B, Roder ME, et al. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf) 1994; 41:217-23.

[75] Hardin DS, Leblanc A, Marshall G, et al. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 2001;281:E1022-8.

[76] Hardin DS, LeBlanc A, Para L, et al. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999;48:1082-7.

[77] Tofe S, Moreno JC, Maiz L, et al. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur J Endocrinol 2005;152:241 -7.

[78] Ergun-Longmire B, Marker J, Zeidler A, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci 2004;1029:260-77.

Was this article helpful?

0 0
Quick Permanent Weight Loss

Quick Permanent Weight Loss

A Step By Step Guide To Fast Fat Loss. Do you ever feel like getting rid of the extra weight of your body? If you do, it‟s quite normal because

Get My Free Ebook

Post a comment